Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that have turned the tables of conventional cancer treatments in certain hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) by achieving US Food and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.795164/full |
| _version_ | 1811307778749235200 |
|---|---|
| author | Pouya Safarzadeh Kozani Pooria Safarzadeh Kozani Milad Ahmadi Najafabadi Fatemeh Yousefi Seyed Mohamad Javad Mirarefin Fatemeh Rahbarizadeh Fatemeh Rahbarizadeh |
| author_facet | Pouya Safarzadeh Kozani Pooria Safarzadeh Kozani Milad Ahmadi Najafabadi Fatemeh Yousefi Seyed Mohamad Javad Mirarefin Fatemeh Rahbarizadeh Fatemeh Rahbarizadeh |
| author_sort | Pouya Safarzadeh Kozani |
| collection | DOAJ |
| description | Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that have turned the tables of conventional cancer treatments in certain hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) by achieving US Food and Drug Administration (FDA) approval based on their successful clinical outcomes. However, this type of therapy has not seen the light of victory in the fight against solid tumors because of various restricting caveats including heterogeneous tumor antigen expression and the immunosuppressive tumor microenvironments (TME) that negatively affect the tumor-site accessibility, infiltration, stimulation, activation, and persistence of CAR-Ts. In this review, we explore strategic twists including boosting vaccines and designing implementations that can support CAR-T expansion, proliferation, and tumoricidal capacity. We also step further by underscoring novel strategies for triggering endogenous antitumor responses and overcoming the limitation of poor CAR-T tumor-tissue infiltration and the lack of definitive tumor-specific antigens. Ultimately, we highlight how these approaches can address the mentioned arduous hurdles. |
| first_indexed | 2024-04-13T09:10:15Z |
| format | Article |
| id | doaj.art-b76c836018194667bee947ab40f244be |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T09:10:15Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b76c836018194667bee947ab40f244be2022-12-22T02:52:54ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-05-011310.3389/fimmu.2022.795164795164Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?Pouya Safarzadeh Kozani0Pooria Safarzadeh Kozani1Milad Ahmadi Najafabadi2Fatemeh Yousefi3Seyed Mohamad Javad Mirarefin4Fatemeh Rahbarizadeh5Fatemeh Rahbarizadeh6Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, IranDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IranDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IranDepartment of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, IranDepartment of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IranDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IranResearch and Development Center of Biotechnology, Tarbiat Modares University, Tehran, IranChimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that have turned the tables of conventional cancer treatments in certain hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) by achieving US Food and Drug Administration (FDA) approval based on their successful clinical outcomes. However, this type of therapy has not seen the light of victory in the fight against solid tumors because of various restricting caveats including heterogeneous tumor antigen expression and the immunosuppressive tumor microenvironments (TME) that negatively affect the tumor-site accessibility, infiltration, stimulation, activation, and persistence of CAR-Ts. In this review, we explore strategic twists including boosting vaccines and designing implementations that can support CAR-T expansion, proliferation, and tumoricidal capacity. We also step further by underscoring novel strategies for triggering endogenous antitumor responses and overcoming the limitation of poor CAR-T tumor-tissue infiltration and the lack of definitive tumor-specific antigens. Ultimately, we highlight how these approaches can address the mentioned arduous hurdles.https://www.frontiersin.org/articles/10.3389/fimmu.2022.795164/fullchimeric antigen receptorimmunotherapysolid tumorsinfiltrationvaccinestumor microenvironment |
| spellingShingle | Pouya Safarzadeh Kozani Pooria Safarzadeh Kozani Milad Ahmadi Najafabadi Fatemeh Yousefi Seyed Mohamad Javad Mirarefin Fatemeh Rahbarizadeh Fatemeh Rahbarizadeh Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? Frontiers in Immunology chimeric antigen receptor immunotherapy solid tumors infiltration vaccines tumor microenvironment |
| title | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
| title_full | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
| title_fullStr | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
| title_full_unstemmed | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
| title_short | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
| title_sort | recent advances in solid tumor car t cell therapy driving tumor cells from hero to zero |
| topic | chimeric antigen receptor immunotherapy solid tumors infiltration vaccines tumor microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.795164/full |
| work_keys_str_mv | AT pouyasafarzadehkozani recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT pooriasafarzadehkozani recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT miladahmadinajafabadi recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT fatemehyousefi recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT seyedmohamadjavadmirarefin recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT fatemehrahbarizadeh recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT fatemehrahbarizadeh recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero |